ロード中...
Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study
BACKGROUND: Middle East respiratory syndrome (MERS) is a severe respiratory illness with an overall mortality of 35%. There is no licensed or proven treatment. Passive immunotherapy approaches are being developed to prevent and treat several human medical conditions where alternative therapeutic opt...
保存先:
| 出版年: | Lancet Infect Dis |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Elsevier Ltd.
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5871563/ https://ncbi.nlm.nih.gov/pubmed/29329957 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1473-3099(18)30002-1 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|